Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,881 total articles
Palo Alto Networks (PANW) sits at the intersection of traditional network security and the emergent need to defend AI attack surfaces. The stock pulled back from $357.53 to trade near $345.81 after a one-day gap, creating a tactical entry for a mid-term swing. Valuation is rich but defendable given platform positioning, recurring revenue mix and so…
Novartis ($156.74) is actively rebuilding its innovation engine with bolt-on M&A and late-stage assets. A clinical readout for a late-stage program (pelacarsen) is expected imminently, and the company just agreed to acquire Myricx Bio for up to $1.5 billion (07/06/2026) to beef up its ADC payload capabilities. We view the risk/reward as favorable f…
Uber's platform economics, sizable free cash flow, and explicit supply deals with autonomous vehicle makers mean robotaxis are a real earnings lever, not just a headline. I lay out an actionable long trade with entry, stop, targets, catalysts and risks tied to deployments and regulation.
Strata Critical Medical (SRTA) combines air logistics with newly integrated perfusion and donor services to create a vertically aligned organ-transplant platform. The Keystone Perfusion deal and guidance for high-teens Adjusted EBITDA growth underpin a mid-term long trade: buy SRTA around current levels with a $7.00 target and a disciplined stop at…
CareDx is sharpening into a higher-margin transplant diagnostics leader. A $170M sale of its Lab Products business and a strong preliminary Q1 2026 update (revenue +39% YoY; Testing Services +48%) create a realistic mid-term trade: buy at current levels with a $38 target and a $24 stop. The company is cash-flow positive and trading at a market cap …
Micron's position as a leading supplier of DRAM and HBM to hyperscalers, backed by strong profitability, free cash flow, and a market cap of roughly $1.11T, suggests the current pullback is an opportunity. I outline a mid-term long trade (45 trading days) that leans on continued AI-driven HBM tightness, upcoming earnings cadence, and industry capac…
Rogers Communications (RCI) is trading near the low end of its 52-week range with a sub-4x P/E, a 4.6% yield and deep technical oversold signals. Recent corporate moves - including taking full control of major sports assets - create a catalyst runway while valuation provides a margin of safety. This trade idea lays out an entry, stop and target wit…
Taylor Devices (TAYD) is a niche industrial manufacturer of shock absorption and energy-control hardware with no debt, double-digit returns on capital, and a modest valuation by several measures. The story is simple: durable cash flow, improving margins, and growing aerospace/defense sales that the market hasn't fully priced. This trade idea outlin…
Newmont (NEM) trades like a deep-value gold major after a painful June drawdown. The balance sheet, free cash flow and buyback activity make it a reasonable tactical long, but higher costs and falling gold prices keep it from being my top pick. This trade targets a recovery into mid-$100s over a 45 trading-day horizon with a strict stop at $90.
Suncor (SU) is trading near $55 after a period of weakness that reflects headline sensitivity rather than a change in the company’s core cash-generating assets. With a market cap near $64.8B, a 3%+ dividend yield, an enterprise value of roughly $83.8B and negative free cash flow last reported at -$841M, the opportunity today is asymmetric: downside…
Boeing's path back to normalized production is the most actionable lever left for the stock. This trade idea buys into measurable improvements on the factory floor and the backlog cadence, with a defined entry at $220, a $280 target and a $190 stop.
Ciena has surged roughly 80% year-to-date but the balance sheet, cash flow generation and direct exposure to the AI infrastructure build make the stock a compelling mid-term swing trade. Valuation is rich on headline multiples, yet modest free cash flow yield, strong liquidity (current ratio 2.73) and secular demand for optical networking justify a…
ON Semiconductor (ON) is commonly pegged as a cyclical automotive supplier. That’s a fair starting point, but recent strategic moves - most notably the $7B Synaptics acquisition - and growing AI/data-center exposure shift the company toward structural growth in edge AI, sensing and power electronics. With a market cap of roughly $36.85B, $1.18B in …
Iberdrola offers a mix of regulated utility stability and predictable renewable growth. This trade targets steady upside over the next 180 trading days with a defined stop to manage grid and regulatory risks.
Marvell's deep portfolio in data-center connectivity, custom ASICs and optics, plus robust free cash flow and a $218B market cap, make it a better asymmetric trade than smaller peers like Credo for investors who want AI-infrastructure exposure. Valuation is rich, so this is a disciplined swing trade with a defined stop and a mid-term horizon.
Navitas Semiconductor has run hard in 2026 on AI optimism and a new DC-DC offering, but an industry push toward 800V power distribution and intensified competition risks compressing margins and shrinking the firm's realistic addressable market. The company trades at a sky-high price-to-sales multiple and negative cash flow — we recommend reducing e…
ZIM is trading at $24.30 against a $35 all-cash bid from Hapag-Lloyd. Even if Israel's regulatory concerns slow or block the deal, ZIM's balance sheet, sub-1.0 PB and recent dividend create a valuation floor that makes the current price an attractive entry for a long trade. This idea lays out an actionable plan with entry, stop and target and a rea…
Calumet (CLMT) has staged a dramatic recovery from its 2025 low, driven by specialty products growth and renewable projects. The stock sits near $36.88 with technical momentum and a manageable float. This trade idea lays out a position trade to test whether recent operational improvements and DOE-backed renewables support a sustainable re-rating.
Nebius Group (NBIS) has sold off sharply after a volatile stretch, but underlying growth indicators - including a rapid revenue ramp and aggressive power capacity expansion - argue for a tactical long. This trade plan targets a recovery toward the mid- to high- $200s over the next 45 trading days with a disciplined stop below structural support.
Sabesp (SBS) is one of Brazil's largest water and sewage operators and remains an execution story: steady cash returns, a modest dividend, and improving technicals create a favorable risk/reward for a mid-term swing. I recommend a tactical long with entry at $5.80, stop at $5.20 and a target of $6.90 over the next 45 trading days.
Mastercard is trading below its 52-week high after a pullback; the business continues to convert transaction growth into high-margin cash flow. With network tokenisation adoption, Click to Pay rollouts, and a balanced capital return profile, this is a trade to buy on pullback with a clear stop and a target near prior highs.
Pure Storage (PSTG) looks positioned to benefit from a renewed hyperscaler spending cycle and enterprise NVMe refreshes. We lay out a position trade that buys into accelerating demand and software margin leverage, with clear entry, target and stop levels and a list of catalysts and risks to watch.
Regis is a cash-generative salon franchisor with outsized free cash flow relative to its market cap. Management's push to reduce underperforming company-owned salons and lean into franchising can unlock value quickly. At $27.50, the stock trades at a compelling free cash flow yield and low multiples; a disciplined entry around the market price with…
Microsoft's enterprise software stack + Azure AI gives it a structural advantage in the AI arms race. This trade targets upside from continued Azure AI consumption and enterprise Copilot rollouts while limiting downside with a pragmatic stop. Mid-term trade (45 trading days) focused on earnings cadence and AI deal flow.
ImmunityBio is a clinical-stage immunotherapy company whose ANKTIVA program just cleared a meaningful regulatory gate. The stock trades at roughly $8.92 with a $9.33B market cap amid heavy short interest and active litigation. For disciplined, risk-tolerant investors the setup offers asymmetric upside to $14 over a 180-day horizon if regulatory mom…
